Celyad (CYAD), a biopharmaceutical company focused on CAR-T cell based therapies, said Tuesday that a patient with relapsed refractory acute myeloid leukemia has achieved the first ever morphologic complete response with its gene-engineered T cells.
The company said the development represents the first time a relapsed refractory acute myeloid leukemia patient reached a complete response with gene-engineered T cells without pre-conditioning lymphodepletion or additional concurrent treatment.
The first dose-level of CYAD-01 T cells were administered without prior conditioning chemotherapy to a cohort of three patients in Celyad’s THINK trial. The trial is being conducted in the US and in Europe and includes two stages: a dose escalation and an extension stage. No dose limiting toxicities or deaths related to the investigational product have been reported.